You are here

Cell Res DOI:10.1038/cr.2012.115

Resistance to EGFR blockade in colorectal cancer: liquid biopsies and latent subclones.

Publication TypeJournal Article
Year of Publication2013
AuthorsKonieczkowski, DJ, Garraway, LA
JournalCell Res
Volume23
Issue1
Pages13-4
Date Published2013 Jan
ISSN1748-7838
KeywordsAntibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Cell Line, Tumor, Cetuximab, Colorectal Neoplasms, DNA, Neoplasm, Drug Resistance, Neoplasm, Humans, Mutation, ras Proteins, Receptor, Epidermal Growth Factor
Abstract

Two recent papers identify KRAS activation as a mechanism of acquired resistance to EGFR blockade in colorectal cancer. In doing so, they suggest that resistance to single-agent EGFR blockade will be unavoidable because these alterations exist as latent subclones within the tumor even prior to the initiation of therapy.

URLhttp://dx.doi.org/10.1038/cr.2012.115
DOI10.1038/cr.2012.115
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/22847744?dopt=Abstract

Alternate JournalCell Res.
PubMed ID22847744
PubMed Central IDPMC3541651
Grant ListT32 GM007753 / GM / NIGMS NIH HHS / United States